Results 91 to 100 of about 2,487 (198)

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available.
Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin   +9 more
doaj   +1 more source

Single-dose nirsevimab prevents RSV infection [PDF]

The Journal of Pediatrics, 2021
Shabir A, Madhi, Eric A F, Simões
openaire   +2 more sources

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.

JAMA pediatrics
Importance During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer's maternal RSV vaccine.
Heidi L. Moline, Ariana P Toepfer, A. Tannis, G. Weinberg, M. Staat, N. Halasa, J. Boom, Eileen J. Klein, John V Williams, Jennifer E Schuster, Leah A. Goldstein, Erin McKeever, Casey M Kalman, Clinton R. Paden, Lydia Atherton, Megha Aggarwal, P. Roychoudhury, P. A. Piedra, Leila C. Sahni, Laura S. Stewart, R. Selvarangan, Marian G Michaels, Elizabeth P. Schlaudecker, Peter G. Szilagyi, J. Englund, Benjamin R. Clopper, Natalie J. Thornburg, Gordana Derado, M. McMorrow, Fatimah S. Dawood   +29 more
semanticscholar   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study

BMJ Public Health
Introduction Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants.
Miguel Angel Casado, Ruth Gil-Prieto, Jaime Pérez-Martín, Ariadna Díaz Aguiló, Samira Soudani, Leticia Platero-Alonso, Juan Luis López-Belmonte, Alberto de la Cuadra-Grande, Javier Álvarez Aldean   +8 more
doaj   +1 more source

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Human Vaccines & Immunotherapeutics
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Narmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, Alberto Malvar-Pintos, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres   +21 more
doaj   +1 more source

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier   +14 more
doaj   +1 more source

Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024)

Vaccines
A systematic review with a meta-analysis was performed to gather available evidence on the effectiveness of monoclonal antibody nirsevimab in the prevention of lower respiratory tract diseases (LRTDs) due to respiratory syncytial virus (RSV) in children ...
Matteo Riccò, A. Cascio, S. Corrado, Marco Bottazzoli, F. Marchesi, Renata Gili, P. Giuri, Davide Gori, P. Manzoni   +8 more
semanticscholar   +1 more source

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Global & Regional Health Technology Assessment
Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to ...
A. Marcellusi, C. Bini, B. Muzii, Samira Soudani, A. Kieffer, Matthieu Beuvelet, E. Bozzola, F. Midulla, Eugenio Baraldi, P. Bonanni, S. Boccalini, L. Orfeo   +11 more
semanticscholar   +1 more source

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis

Frontiers in Pediatrics
ObjectiveRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications.
Shunli Liu, Shunli Liu, Yan Wang, Yan Wang, Yang Cao, Yang Cao, Huiling Song, Huiling Song, Zhiqing Tian, Zhiqing Tian, Xue Li, Xue Li, Lan Huang, Lan Huang   +13 more
doaj   +1 more source

Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

Journal of the Pediatric Infectious Diseases Society
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent ...
Ron Dagan, L. Hammitt, B. Seoane Nuñez, M. Baca Cots, M. Bosheva, S. Madhi, William J. Muller, H. Zar, Yue Chang, Alexander Currie, Amy Grenham, Manish Shroff, Therese Takas, V. S. Mankad, Amanda Leach, T. Villafana   +15 more
semanticscholar   +1 more source